Abstract Introduction: Subtotal thyroidectomy preserves glandular tissue intending to maintain hormonal autonomy; however, the viability of the remnant is unpredictable, complicating postoperative pharmacological management. Objective: To analyze available scientific evidence on the indication, dosage regimens, and clinical outcomes of levothyroxine use in patients undergoing subtotal thyroidectomy. Methodology: A systematic review was conducted following the PRISMA 2020 statement. A search in indexed databases (PubMed, Scielo, ScienceDirect, Cochrane) identified 50 relevant studies published in the last 5 years. Results: Evidence indicates that a significant proportion of patients develop late-onset hypothyroidism due to remnant exhaustion or require suppressive therapy to prevent goiter recurrence. Unlike total resection, dosing is complex and empirical, with a high risk of iatrogenic subclinical hyperthyroidism due to overtreatment, impacting cardiovascular and bone health. Conclusions: Levothyroxine therapy is frequently necessary and effective but demands strict TSH monitoring to personalize dosage, balancing recurrence prevention with patient safety.
Llerena Freire LF (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: